Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro

被引:0
|
作者
Agrawal, M [1 ]
Brauer, PR [1 ]
机构
[1] CREIGHTON UNIV,SCH MED,DEPT BIOMED SCI,OMAHA,NE 68178
关键词
neural crest; migration; plasminogen activator; transforming growth factor-beta;
D O I
10.1002/(SICI)1097-0177(199611)207:3<281::AID-AJA5>3.3.CO;2-9
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Proper migration and differentiation of neural crest (NC) cells are required for normal development of craniofacial structures, heart and great vessels, sensory and autonomic nervous systems, and other organs within vertebrate embryos. Serine-protease inhibitors reduce NC cell migration in vitro, suggesting the extracellular proteases are important mediators of NC cell migration, While plasminogen activator activity levels are high in NC cells relative to other embryonic tissues, its ability to regulate NC cell migration has not been specifically tested in vivo or in vitro. In this study, we show urokinase-type plasminogen activator (uPA) regulates NC cell migration in vitro through its ability to convert plasminogen to plasmin,. Using a transfilter migration assay, NC cell migration was measured in the presence or absence of plasminogen, Our results showed that plasminogen significantly enhanced NC cell migration. This increase could not be attributed to differences in initial NC cell attachment or cytotoxicity and did mot require a chemotactic gradient. The plasminogen-enhanced NC cell migration was blocked by aprotinin (a plasmin inhibitor) and was mimicked by the direct addition of plasmin to the NC cells, indicating that the plasminogen effect was mediated through plasmin generation. Furthermore, anticatalytic-uPA antibody blocked the plasminogen-enhanced NC cell migration showing that NC cell-associated uPA activity was required for this effect, Finally, decreasing NC-uPA activity by treating cells with transforming growth factor-beta, also blocked the plasminogen-dependent increase in cell migration, These data show that in vitro, NC cell migration is regulated by NC-associated uPA activity suggesting that growth factor-regulation of this activity may play a major role in regulating NC cell migratory capacity in vivo. (C) 1996 Wiley-Liss, Inc.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 50 条
  • [21] Ras regulation of urokinase-type plasminogen activator
    Lengyel, E
    Ried, S
    Heiss, MM
    Jäger, C
    Schmitt, M
    Allgayer, H
    REGULATORS AND EFFECTORS OF SMALL GTPASES, PT G, 2001, 333 : 105 - 116
  • [22] Urokinase-type plasminogen activator inhibitors.
    Squires, N
    McGee, D
    Allen, D
    Hruzewicz, W
    Spencer, J
    Sprengeler, P
    Katz, B
    Luong, C
    Mackman, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U51 - U51
  • [23] Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator
    Jo, MJ
    Thomas, KS
    Marozkina, N
    Amin, TJ
    Silva, CM
    Parsons, SJ
    Gonias, SL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 17449 - 17457
  • [24] Urokinase-type plasminogen activator promotes corneal epithelial migration and nerve regeneration
    Sugioka, Koji
    Nishida, Teruo
    Kodama-Takahashi, Aya
    Murakami, Junko
    Fukuda, Masahiko
    Matsuo, Osamu
    Kusaka, Shunji
    EXPERIMENTAL EYE RESEARCH, 2023, 233
  • [25] Multiparity upregulates placental plasminogen and urokinase-type plasminogen activator
    Cortina, Maria E.
    Litwin, Silvana
    Hawila, Maria R. Rial
    Miranda, Silvia
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2017, 77 (04)
  • [26] Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration
    Pliyev, Boris K.
    Antonova, Olga A.
    Menshikov, Mikhail
    MOLECULAR IMMUNOLOGY, 2011, 48 (9-10) : 1168 - 1177
  • [27] Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors
    Yoshizawa, Kunio
    Nozaki, Shinichi
    Kitahara, Hiroko
    Kato, Koroku
    Noguchi, Natsuyo
    Kawashiri, Shuichi
    Yamamoto, Etsuhide
    ONCOLOGY REPORTS, 2011, 26 (06) : 1555 - 1560
  • [28] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
    Zhou, Huanqin
    Wu, Xianguo
    Lu, Xingguo
    Chen, Gang
    Ye, Xiongwei
    Huang, Jian
    THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
  • [29] Urokinase-type plasminogen activator receptor: A beacon of malignancy?
    Drapkin, Ronny
    Clauss, Adam
    Skates, Steven
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5643 - 5645
  • [30] Small molecule inhibitors of urokinase-type plasminogen activator
    Rockway, TW
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (06) : 773 - 786